Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but it’s the arbitrators that jack up prices for those who can least afford them. → Read More
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiati… → Read More
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive. → Read More
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine. → Read More
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma. → Read More
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters. → Read More
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearl… → Read More
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast. → Read More
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized. → Read More
The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities. → Read More
As the country faces a rise in new infections driven by the omicron BA.5 subvariant of the coronavirus, about 70% of people 50 and older who got a first covid-19 booster shot haven’t received… → Read More
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail. → Read More
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success and might have overshadowed the government’s covid-fighting strategy. → Read More
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market? → Read More
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face compl… → Read More
Federal health officials haven’t taken a clear position on whether a high-dose influenza vaccine — on the market since 2010 — is the best choice for people 65 and older. Many in that group already … → Read More
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time… → Read More
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work. → Read More
In the middle of a measles outbreak in 1977, the Los Angeles school system required students to be inoculated or stay out of class. Other school systems followed the practice. Will it work again no… → Read More
Although it’s possible to buy travel insurance that provides some health coverage, the devil is in the fine print. Obama-era laws that prevent refusal of payment for preexisting conditions don’t ap… → Read More